Prothena Corporation plc

Add to watchlist
€32.6
Last updated:06/09/2021
0PT: F
Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease … Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-153.237M
-155.645M
-1.57%
-77.677M
+50.09%
-111.144M
-43.08%
Cashflow
Sum up money going in and out company
-131.183M
-28.276M
+78.45%
-52.969M
-87.33%
-80.362M
-51.72%
Total liabilities
All combined debts and obligations
89.14M
175.798M
+97.22%
146.347M
-16.75%
148.969M
+1.79%
Company profile
CEO
Mr. Gene G. Kinney
Market capitalization
Small (1.47B)